Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 24 Apr, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Recent Articles
- Cannabis Shares Retreat from Rally on Narrow Scope of Rescheduling
- White House Accuses China of Industrial-Scale Distilling of AI Models
- Vox Momenti: From India with Ambition
- AI Turns Engineers and Project Managers into 'Builders'
- US Farmers Bet on Peas and Lentils on GLP-1-Related Protein Maxxing Trend
- Lee's Visit Produces 73 S. Korea-Vietnam Business Deals
- Biggest IPO Wave Ever Creates $3 Trillion Value on Zero Profits
- Marijuana Products Reclassified As Less-Dangerous Drug
- China's Global EV Push Backed by Ambition and Hard Domestic Landscape
- Keurig Dr Pepper Beats As Strong Beverage Demand Offsets Coffee Weakness